Structure Therapeutics Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Raymond C. Stevens
- Full Time Employees
- 281
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 611 Gateway Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Feb 3, 2023
- CIK
- 0001888886
- Website
- structuretx.com
- Similar Companies
- Business
- Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company that develops novel oral small molecule therapeutics targeting G-protein coupled receptors (GPCRs) for chronic diseases with unmet medical needs, including obesity, type 2 diabetes, pulmonary fibrosis, and cardiopulmonary conditions; its lead candidate, aleniglipron (GSBR-1290), is an oral glucagon-like peptide-1 receptor (GLP-1R) agonist in Phase 2b trials (ACCESS and ACCESS II) for obesity and overweight with topline data expected by year-end 2025; additional pipeline assets include ACCG-2671 and ACCG-3535, oral amylin receptor agonists in IND-enabling studies and preclinical development for obesity with Phase 1 initiation planned by late 2025, ANPA-0073, an oral apelin receptor (APJR) agonist phase 2-ready for muscle-sparing weight loss, LTSE-2578, a lysophosphatidic acid 1 receptor (LPA1R) antagonist that completed Phase 1 for idiopathic pulmonary fibrosis, discovery programs modulating glucose-dependent insulinotropic polypeptide receptor (GIPR) with agonist, dual GLP-1R/GIPR agonist and antagonist candidates for obesity, and glucagon receptor (GCGR) program with agonist and dual GLP-1R/GCGR agonist hits; the company leverages structure-based drug discovery, computational chemistry, and structural biology platforms to optimize binding and pharmacokinetics for metabolic, inflammatory, and cardiopulmonary disorders. Founded in 2016 and formerly known as ShouTi Inc., Structure Therapeutics is headquartered in South San Francisco, California, with operations in the United States and China targeting global patient populations. Recent developments include completion of enrollment in aleniglipron Phase 2b obesity studies, announcement of three additional aleniglipron clinical studies for competitive positioning, advancement of oral amylin programs, asset sale of a program to Exelixis generating $10 million upfront with $5.2 million received, $547 million in financing secured in 2024, and a strengthened cash position of $883.5 million as of year-end 2024 funding operations through 2027.
Company News
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi
The Next Phase Of The Obesity Drug Race
Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Structure's experimental obesity pill shows no signs of liver injury
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
If Viking Therapeutics Is Acquired, Here’s Who Wins
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
Monashee Scales Back Its Bet on Structure Therapeutics
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing